2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 98

Costs of Musculoskeletal Diseases in the United States, 1996-2011: Population Growth, Population Aging, Health Care Utilization, or Prices?
Abstract Number: 2709

Could a Fibroblast-Free Environment Protect the Microcirculation in Systemic Sclerosis? Evidence from Retinal Vascular Imaging Research
Abstract Number: 395

Could Osteoprotegerin and TNF-Related Apoptosis-Inducing Ligand Assessments Help Us to Manage Early Rheumatoid Arthritis? Results from the Espoir Cohort
Abstract Number: 296

Countermeasures Against Methotrexate Intolerance in Juvenile Idiopathic Arthritis Instituted By Parents Show No Effect
Abstract Number: 101

Country of Residence and Its Wealth Determine Disease Activity Levels in RA: Results from Multi-National Study Across 17 Countries (COMORA)
Abstract Number: 2329

Course and Outcome of Rehabilitation Care in Different Rheumatological Diagnosis Groups. a Descriptive Study Using the STAR-Etic Registry
Abstract Number: 1511

COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Abstract Number: 2249

Criteria for Clinically Important Worsening in Knee and Hip Osteoarthritis
Abstract Number: 1315

Cross-Sectional Evaluation of Hydroxychloroquine (HCQ) Therapy in Children with Juvenile Dermatomyositis (JDM) Enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 1227

Cryopyrinopathy with a Myeloid-Specific NLRP3 Mutation
Abstract Number: 1966

CTLA4-Ig (abatacept) Modulate in Vitro the ICAM1 and VEGFR-2 Expression in Human Endothelial Cells
Abstract Number: 2144

Cuantification of Hand Bone Mineral Density By Radiogrammetry and Dual X-Ray Absorptiometry in Early Arthritis Patients
Abstract Number: 1525

Cumulative Clinical Â Response in Â RheumatoidÂ Arthritis Patients with Â Rituximab Repeated Courses after Failure to TumorÂ Necrosis Factor Inhibitors in RoutineÂ Clinical Practice Â
Abstract Number: 1582

Cumulative Inflammatory Burden Is Independently Associated with Increased Arterial Stiffness in Patients with Psoriatic Arthritis
Abstract Number: 1531

CUT-Off LEVEL of Adalimumab and Prevalence of Antibodies ANTI-Adalimumab in Patients with Ankylosing Spondylitis: Results from a LOCAL Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].